1. WTAP-induced N 6 -methyladenosine of PD-L1 blocked T-cell-mediated antitumor activity under hypoxia in colorectal cancer.
- Author
-
Liu QZ, Zhang N, Chen JY, Zhou MJ, Zhou DH, Chen Z, Huang ZX, Xie YX, Qiao GL, and Tu XH
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, RNA-Binding Proteins metabolism, RNA-Binding Proteins genetics, T-Lymphocytes immunology, T-Lymphocytes metabolism, Cell Proliferation, Gene Expression Regulation, Neoplastic, RNA Splicing Factors genetics, RNA Splicing Factors metabolism, Female, Tumor Hypoxia genetics, Cell Cycle Proteins, Adenosine analogs & derivatives, Adenosine metabolism, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Colorectal Neoplasms immunology, Colorectal Neoplasms metabolism, B7-H1 Antigen metabolism, B7-H1 Antigen genetics
- Abstract
N
6 -Methyladenosine (m6 A) is a important process regulating gene expression post-transcriptionally. Programmed death ligand 1 (PD-L1) is a major immune inhibitive checkpoint that facilitates immune evasion and is expressed in tumor cells. In this research we discovered that Wilms' tumor 1-associated protein (WTAP) degradation caused by ubiquitin-mediated cleavage in cancer cells (colorectal cancer, CRC) under hypoxia was inhibited by Pumilio homolog 1 (PUM1) directly bound to WTAP. WTAP enhanced PD-L1 expression in a way that was m6 A-dependent. m6 A "reader," Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) identified methylated PD-L1 transcripts and subsequently fixed its mRNA. Additionally, we found that T-cell proliferation and its cancer cell-killing effects were prevented by overexpression of WTAP in vitro and in vivo. Overexpression prevented T cells from proliferating and killing CRC by maintaining the expression of PD-L1. Further evidence supporting the WTAP-PD-L1 regulatory axis was found in human CRC and organoid tissues. Tumors with high WTAP levels appeared more responsive to anti-PD1 immunotherapy, when analyzing samples from patients undergoing treatment. Overall, our findings demonstrated a novel PD-L1 regulatory mechanism by WTAP-induced mRNA epigenetic regulation and the possible application of targeting WTAP as immunotherapy for tumor hypoxia., (© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)- Published
- 2024
- Full Text
- View/download PDF